Reflections on ALFC 2024

Reflecting on the Advanced Lateral Flow Conference 2024, I am struck by the breadth and depth of innovation evident in the presentations and discussions. This year’s conference was not only a testament to the resilience and adaptability of the lateral flow industry, but also a look into the future of global healthcare. The convergence of experienced professionals, emerging leaders, and groundbreaking technologies underscored the important role community, idea sharing, and shared commitment plays in advancing global health. As both host and participant, I found the conversations and sessions enlightening and the collective focus invigorating. It is this spirit of mutual respect and support that continues move our industry forward.

A Focus on Commercialization and Funding

New to ALFC 2024, our organizing committee selected speakers and panelists who could highlight the commercialization and funding issues influencing our industry. 

One such speaker was Giles Hamilton, Chairman of Panacea, Transdermal Dx, and SciLogica. In his enlightening session titled “Investment Pathways in Lateral Flow: Shaping the Future of Rapid Diagnostics”, Hamilton highlighted a critical healthcare gap: that nearly half the global population lacks access to diagnostics according to the Lancet Commission on Diagnostics and WHO data. Hamilton’s talk drew upon his experience in spearheading at-home testing including financing over 100 lateral flow deals. He presented a future where point-of-care diagnostics are central to healthcare. With a compound annual growth rate (CAGR) of 10.7% by 2025 (compared to 7.4% CAGR for central labs), the PoC diagnostics market will reshape the healthcare landscape in the coming years. 

Despite 248 active US venture capital funds focused on pre-revenue MedTech and point-of-care testing, obstacles persist. For instance, Hamilton underscored the need for products that deliver results in under five minutes, with initial consumable costs of goods sold (COGs) at $2-3 eventually dropping below $1 at scale. 

How do we meet these challenges? Hamilton’s recommendations included ensuring a compelling clinical use case and cost control at all stages of development along with the need to engage with payers to refine the technology and Minimum Viable Products. He also pointed out the often-overlooked sources of non-dilutive government and foundation grant funding which offer alternate structures including license royalties and joint funding. He spotlighted the potential of corporate investment syndicates, like those at Medtronic and J&J DevCo, who review thousands of companies each year underscoring the competitive nature of platform financing.  

Hamilton’s advice to lateral flow companies was clear: keep an open mind on business models, select development and target markets carefully, and ensure plans are aligned with US-centric POCT adoption and prioritization. Such a nuanced understanding of the funding landscape is critical when aiming to bring transformative diagnostic solutions to market. Early feedback from attendees indicates that this was an important session and I certainly agree.

Innovation Award: A Spotlight on Industry Leaders

Industry innovation is a collective effort, and the ALFC serves as a needed platform for sharing technological advances. A particularly memorable aspect of the program was the Innovation Award which showcased pioneering products and technologies. The three finalists exemplified the spirit of innovation that drives our market forward. 

LFAnt emerged as the audience-selected winner with its revolutionary product, the Compact – the world’s first handheld and portable magnetic lateral flow platform. This device enables quantitative testing from point of care anywhere, making advanced diagnostics accessible in a range of settings. In addition to being recognized by their peers, the LFAnt team also took home a $10,000 cash prize. 

The Fraunhofer Institute’s CampyTube presented a unique integration of lateral flow and molecular detection in a single vial. This seamless, simple and sophisticated combination could open new avenues for rapid, on-site detection of various pathogens. 

inne‘s STRIP 2.0 was another standout, offering a novel approach to measuring the hormone progesterone in saliva with impressive sensitivity. Beyond technical achievements, the STRIP 2.0 significantly reduces plastic waste and enhances user experience, addressing both sustainability and usability concerns. We heard more from inne’s founder and CEO, Eirini Rapti, in a joint “case study” session titled “Full Circle Innovation: A Collaborative Approach to Product Lifecycle Excellence”. In this 3-part session, Rapti represented “product”, while Keith Kopitzke, Principal Engineer, DCN Dx, presented engineering, and Ted Meigs, Kinematic Automation (now part of Ascential Medical and Life Sciences) represented manufacturing. 

These Innovation Award finalists demonstrated exceptional technical ingenuity and a commitment to improving healthcare outcomes and patient experiences. Congratulations again for your achievements! 

New Awards in 2024

Award additions for 2024 included the Leadership in Diagnostics, the Lifetime Achievement Award, and Poster Awards. The Leadership in Diagnostics Award acknowledges an individual or organization who have influenced the industry by fostering collaboration and contributing to the evolution lateral flow diagnostics. It recognizes individuals whose careers have been marked by sustained and significant impacts, setting a benchmark for commitment and excellence in the industry. 

For the 2024 Poster Awards, there was a tie between two remarkable contributors: Dr. Nicolas Heureux’s team at Kimialys and John Kelly, the Founder and CEO of Atomo Diagnostics. Dr. Heureux, with a background in immuno and organic chemistry, is at the forefront of advancing LFA technologies. His work on SPR-based biophysical studies and his contribution to the Rapid Antibody Pair Selection for TnI Lateral Flow Assay via Multiplexed SPRi poster is important research with far reaching implications. John Kelly brings over two decades of experience in redefining medical devices and dedication to enhancing diagnostic usability and performance. Also a session speaker, both Kelly’s poster and talk focused on Atomo’s important work developing a user-centric LFA cassette design for improved blood sampling for POCT devices. 

The Leadership in Diagnostics Award was proudly presented to Ted Meigs, whose extensive experience in automation and design has influenced the LFA industry significantly. As a co-founder of Kinematic Automation (now part of Ascential Medical and Life Sciences), Meigs has been a pillar in the diagnostic community, holding numerous patents and setting industry standards in manufacturing processes. Meigs and his team are recognized globally as leaders in manufacturing automation which highlights ability to foster collaboration across the field. 

The Lifetime Achievement Award honored Dr. Thomas Tisone for his visionary entrepreneurship and substantial contributions to lab automation. His commitment to innovation and customer focus has been key in BioDot’s success, leading to products integral to the diagnostics industry. Tisone’s philosophy of “We Can Do That” reflects an approach that inspired a culture of ingenuity, service and contributing to BioDot’s status where the average employee tenure exceeds two decades. 

These awardees exemplify the spirit of excellence and innovation that defines the lateral flow industry. Their achievements not only highlight the advances in LFA technology but also set benchmarks for leadership, commitment, and research excellence. We were honored to have such esteemed and deserving awardees.

Future Directions and Continued Collaboration

The insights and discussions at ALFC 2024 underscored the importance of collaboration and cross-disciplinary approaches. The integration of digital technologies, including AI and machine learning, was a recurring theme which highlighted a broader trend towards more intelligent, user-friendly diagnostics. 

Looking to the future, it is clear that the boundaries of what lateral flow assays can achieve are expanding. The potential for LFAs to play a more significant role in personalized healthcare, environmental monitoring, and global disease surveillance is immense.

A Special Thanks to Our Sponsors

ALFC 2024’s success was driven the support and engagement of our sponsors. It is with deep gratitude that we acknowledge the role our sponsors played.  

Our sponsors are our exhibitors and together they created a dynamic exhibit room. More than a space for breaks, it was a cornerstone for pivotal discussions, insights, and learning. Thanks to Multisorb, our Exhibit Lounge sponsor, we were fueled by coffee and snacks each day.  Of all the life science conferences I’ve attended over the year’s ALFC’s exhibit room stands out as the most engaging I’ve experienced. Every visit to this vibrant area was a true educational opportunity—and I heard this sentiment echoed often from our attendees. The depth of knowledge and innovation showcased by our sponsors made the Exhibit Room a true learning experience for all.  

To our sponsors, we extend our heartfelt thanks. Your financial support and active participation throughout the ALFC planning process were indispensable. The event thrives on your contributions, without you we could not provide the value that our attendees have come to expect. 

We are delighted that most sponsorships for ALFC 2024 were sold out due to high demand. Looking ahead to ALFC 2025, we are opening up early sponsorship. For those interested in sponsoring and playing a key role in next year’s event, we encourage you secure your spot early. Your early commitment allows us to plan for an even more impactful event, building on this year’s success and forging new frontiers in the lateral flow assay industry.

A Collective Journey Towards Innovation

The contributions of each attendee, speaker, and sponsor at the conference are invaluable in shaping the future of our industry. As we “flow forward”, let us continue the spirit of collaboration and innovation that defines the ALFC. Together, we can address the complex diagnostic challenges and make a meaningful impact on the lives of people around the world. 

Thanks to all who participated in ALFC 2024. Your dedication to advancing lateral flow technology is not only inspiring but essential in shaping a healthier and more informed world. We hope to see you at the next ALFC, which will be held October 14-15, 2025.

Sincerely,